Lurbinectedin (BioDeep_00000837583)
代谢物信息卡片
化学式: C41H44N4O10S (784.2778004)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O
InChI: InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
描述信息
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- P Aviles, R Altares, L van Andel, R Lubomirov, S Fudio, H Rosing, F M Márquez Del Pino, M M Tibben, G Benedit, L Nan-Offeringa, X E Luepke Estefan, A Francesch, A Zeaiter, C Cuevas, J H M Schellens, J H Beijnen. Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
Drug metabolism and disposition: the biological fate of chemicals.
2022 04; 50(4):327-340. doi:
10.1124/dmd.121.000668. [PMID: 35042701] - Carlos Fernández-Teruel, Rubin Lubomirov, Salvador Fudio. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
Journal of clinical pharmacology.
2021 09; 61(9):1206-1219. doi:
10.1002/jcph.1886. [PMID: 33914350] - Salvador Fudio, Josep Tabernero, Vivek Subbiah, Sant P Chawla, Victor Moreno, Federico Longo, Rafael Lopez, Antonio Anton, Jose Manuel Trigo, Geoffrey Shapiro, Woondong Jeong, Victor Manuel Villalobos, Rubin Lubomirov, Carlos Fernandez-Teruel, Vicente Alfaro, Valentina Boni. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
Cancer chemotherapy and pharmacology.
2021 01; 87(1):113-124. doi:
10.1007/s00280-020-04153-6. [PMID: 33108504] - Carlos Fernandez-Teruel, Ignacio Gonzalez, Iñaki F Trocóniz, Rubin Lubomirov, Arturo Soto, Salvador Fudio. Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.
Clinical pharmacokinetics.
2019 03; 58(3):363-374. doi:
10.1007/s40262-018-0701-2. [PMID: 30090974] - L van Andel, H Rosing, R Lubomirov, P Avilés, S Fudio, M M Tibben, L Nan-Offeringa, J H M Schellens, J H Beijnen. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.
Journal of pharmaceutical and biomedical analysis.
2018 Sep; 158(?):160-165. doi:
10.1016/j.jpba.2018.05.053. [PMID: 29883879] - E Erba, M Romano, M Gobbi, M Zucchetti, M Ferrari, C Matteo, N Panini, B Colmegna, G Caratti, L Porcu, R Fruscio, M V Perlangeli, D Mezzanzanica, D Lorusso, F Raspagliesi, M D'Incalci. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
Biochemical pharmacology.
2017 11; 144(?):52-62. doi:
10.1016/j.bcp.2017.08.001. [PMID: 28782526] - Tiziana Pernice, Alan G Bishop, Maria Jose Guillen, Carmen Cuevas, Pablo Aviles. Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma.
Journal of pharmaceutical and biomedical analysis.
2016 May; 123(?):37-41. doi:
10.1016/j.jpba.2016.01.043. [PMID: 26871278]